Tern portfolio company Talking Medicines reports record revenue bookings

Tern

Tern Plc (LON:ERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has noted that Talking Medicines Limited, a company in which Tern currently holds 23.8% of the equity, has announced an update on its Q1 2024 performance, extracts of which are set out below.

Extracts from the Talking Medicines announcement:

“Talking Medicines, a pioneering leader in healthcare intelligence leveraging advanced data science and artificial intelligence, is pleased to announce a strong start to 2024, marked by record revenue bookings and significant advancements in its innovative platform, Talking Medicines Drug-GPT.

In the first quarter of 2024, Talking Medicines achieved significant success with its Talking Medicines Drug-GPT platform, which aims to revolutionise access to intelligence on pharmaceutical medicine brands and disease areas.  This innovative technology has garnered substantial interest from leading global healthcare advertising agencies, who recognise its potential to transform strategies for pharmaceutical clients.

Among Talking Medicines’ clients are some of the world’s most prominent healthcare advertising agency networks, reaffirming the platform’s efficacy in providing key insights derived from aggregated patient and healthcare professional conversations.  By tapping into previously unseen data, Talking Medicines empowers its clients to drive better strategies and make informed decisions in relation to the pharmaceutical landscape.

Furthermore, Talking Medicines has forged strategic partnerships with both open and closed data communities, solidifying its commitment to expanding access to crucial insights.  Notable among these partnerships is the collaboration with data aggregator Socialgist, which enables Talking Medicines to tap into millions of public conversational sites, enriching the Talking Medicines Drug-GPT platform with a wealth of diverse data sources.

Speaking on these achievements, Jo Halliday CEO expressed excitement about the company’s trajectory and the transformative impact of Talking Medicines Drug-GPT on the healthcare industry: “We are thrilled by the broad response to Talking Medicines Drug-GPT and our strategic partnerships. This success underscores our dedication to empowering healthcare stakeholders with actionable insights derived from advanced data science and artificial intelligence.”

Looking ahead, Talking Medicines remains committed to driving innovation and fostering collaborations that enhance healthcare decision-making through intelligence globally.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Tern Open Offer Oversubscribed at 114%

Tern Plc (LON:TERN) announces a successful Open Offer, with over 114% take-up from shareholders, raising £340,140 for its IoT technology initiatives.

Tern’s Bruce Leith appointed Executive Chairman of Purple Transform

Tern Plc (LON:TERN) enhances its strategic position as Bruce Leith steps in as Executive Chairman of Purple Transform Limited, driving growth in IoT investments.

Tern launches underwritten open offer to raise £340,140

Tern Plc has launched an underwritten Open Offer to raise £340,140 through the issuance of shares, benefiting qualifying shareholders with an attractive discount.

UK Technology Stocks in Demand as Investors Switch from US Tech

A combination of more attractive valuations, sector-specific innovation, and growth potential is drawing investors to UK-listed technology stocks.

Tern updates on Sure Ventures’ £1.52 million sale of Getvisibility

Tern Plc highlights Sure Ventures PLC's strategic sale of Getvisibility, anticipating a £1.52 million cash inflow to enhance shareholder value and support growth.

Tern portfolio company Device Authority partners with Microsoft and CyberArk

Tern Plc announces Device Authority's partnership with Microsoft and CyberArk to enhance IoT security in manufacturing, aligning with NIST's latest framework.

Search

Search